Why the study?
Patients with type 2 diabetes mellitus require a multilevel therapeutic approach for primary and secondary prevention of cardiovascular disease, motivating a summary of recent high-level evidence.
Design
Literature review
Authors
Loading...
Summarizes recent pharmacotherapy evidence for CVD in T2DM; leaves open optimal sequencing and combinations pending higher-level trials.
A comprehensive review highlighting the integration of novel drug classes with pleiotropic effects into the standard pharmacological management of cardiovascular disease in patients with type 2 diabetes.
Patoulias et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: